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Abstract
The role of endoscopic retrograde cholangiopancreatography (ERCP) has
dramatically changed in the last years, mainly into that of a therapeutic
procedure. The treatment of benign biliary disease, like “difficult”
choledocolithiasis, with endoscopic papillary large balloon dilation combined
with endoscopic sphinterotomy has proven an effective and safe technique.
Moreover, safety in ERCP has improved as well, with the prevention of post-
ERCP pancreatitis and patient-to-patient transmission of infections. The advent of
self-expandable metal stenting has radically changed the management of
biliopancreatic malignant strictures, while the role for therapy of benign
strictures is still controversial. In addition, cholangioscopy (though the direct
visualization of the biliopancreatic ductal system) has allowed for
characterization of indeterminate biliary strictures and facilitated rescue therapy
of large biliary stones deemed removable. Encouraging data from tissue ablation
techniques, such as photodynamic therapy and radiofrequency ablation, need to
be confirmed by large sample size clinical controlled trials. On the other hand, we
have no drug-coated stents yet available to implant and evidence for the use of
biodegradable stents is still weak. The competency and privileging of ERCP and
endoscopic ultrasonography have been analyzed longer but the switch between
the two procedures, at the same time, is becoming ordinary; as such, the
endoscopist interested in this field should undergo parallel edification through
training plans. Finally, the American Society for Gastrointestinal Endoscopy’s
statement on non-anesthesiologist administration of propofol for gastrointestinal
endoscopy is not actually endorsed by the European Society of Anaesthesiology,
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having many medical-legal implications in some European countries.
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Core tip: Endoscopic retrograde cholangiopancreatography (ERCP) has seen radical
changes within the last three decades. The development of endoscopic ultrasonography
and other imaging technologies has changed the role of ERCP from a diagnostic tool to a
unique therapeutic and imaging platform. New technological developments in ERCP for
diagnosis and treatment have been slow to progress, thus increasing the necessity of
interest in diagnostic and therapeutic fields.
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INTRODUCTION
Endoscopic retrograde cholangiopancreatography (ERCP) has seen radical changes
within the last three decades. The development of endoscopic ultrasonography (EUS)
and other imaging technologies has changed the role of ERCP from a diagnostic tool
to a unique therapeutic and imaging platform. New technological developments in
ERCP for diagnosis and treatment have been slow to progress, thus increasing the
necessity of interest in diagnostic and therapeutic fields.
Some critical dilemmas, like the management of "difficult" choledocolithiasis or the
decrease of ERCP-related complications like pancreatitis, have been partially solved,
while some others remain. For instance, the direct visualization into the biliary tree via
cholangioscopy (CS) allows for targeted tissue sampling or stone management. The
self-expandable metal stent (SEMS) has also dramatically changed the management of
biliopancreatic malignant strictures while the role of treatment for benign strictures is
still  controversial.  In  addition,  emerging  alerts  from  the  Food  and  Drug
Administration  (commonly  referred  to  as  the  ‘FDA’)  to  a  potential  association
between multidrug-resistant bacteria and duodenoscopes have opened new scenarios
to endoscope reprocessing procedures and stimulated the Industry to improve the
research in this field as well.
Initially, EUS was introduced as a purely diagnostic procedure. Along with ERCP,
technological development has gradually changed the role of EUS to therapeutic
application  as  well.  EUS  and  ERCP  share  many  clinical  indications,  including
equipment and devices,  at the same time for the same patient;  thus, in a manner
greater than their competitors, they are truly complementary, with remarkable ability
for mutual aid. This “shared approach” is changing our minds more and more in
terms of training and the learning curve. The newly developed ablation therapy,
tissue sampling, and endoscopic ultrasound-guided ERCP are leading us into a new
dimension, wherein the future biliopancreatic endoscopy might match with genomic
research to develop “personalized therapy” for our patients.
This review will critically analyze the big and small steps which have been made
since ERCP has been introduced, with a look into the future.
WHAT HAS CHANGED IN THE PAST FEW YEARS?
Management of "difficult" choledocolithiasis
The so-called “difficult  stones” are characterized as biliary stones that cannot be
extracted easily with a basket or balloon after endoscopic sphincterotomy (EST) or
endoscopic papillary balloon dilatation (commonly known as EPBD), mainly due to
stone size (diameter > 15 mm), consistency or anatomical variations (i.e. postsurgical
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anatomy, diverticula, duodenal strictures). In these cases, temporary stent insertion or
additional endoscopic procedures, like mechanical lithotripsy or extracorporeal shock
wave lithotripsy, are performed with the need of multiple ERCP procedures and
eliciting several complications. For these reasons, alternative approaches have been
suggested. One of the most frequently used among these is the endoscopic papillary
large balloon dilation (EPLBD) combined with EST, as described for the first time by
Ersoz et al[1] and having a high success rate (90%) in extracting large stones in a single
session and low complication rate (16%).
These  findings  have  improved  the  endoscopist’s  clinical  practice  since  some
features, like large bile duct stones on cholangiography or cross-sectional imaging and
distal bile duct strictures, can easily guide our choice on when to perform EPLBD or
not.  This  technique is  relatively safe,  however careful  evaluation of  radiological
imaging  is  mandatory  since  the  diameter  of  the  balloon  should  not  exceed  the
diameter of the distal bile duct and the EPLBD should not be performed when the
distal bile duct is not dilated to avoid the risk of perforation[2]. A recent meta-analysis
on EST plus EPLBD versus EST alone for choledocholithiasis showed fewer overall
complications  (OR  =  0.53,  95%CI:  0.33-0.85,  P  =  0.008)  and  decreased  use  of
mechanical lithotripsy (OR = 0.26, 95%CI: 0.08-0.82, P = 0.02) in the EST plus EPLBD
group, with no significant differences regarding adverse events and stone clearance[3].
More recently, Hakuta et al[4]  evaluated short- and long-term outcomes of EPLBD
without EST and EPBD for large stones; in a propensity-matched analysis involving
44 patients, EPLBD without EST was significantly more effective for removal of large
stones but showed worse long-term outcomes compared to EPBD. EPLBD in patients
with periampullary diverticula was found to be safe in a multicentric case series
involving four Italian ERCP high-volume centers with complications reported in 8/80
patients and, among these, only 1 severe (duodenal perforation)[5].
CS
CS allows direct visualization of the biliopancreatic ductal system. Initially born as an
adjunct  procedure  performed  during  surgery  or  percutaneous  transhepatic
cholangiography, today CS is mainly performed perorally during ERCP[6]. Different
types  of  CS are  possible;  the  single-operator  CS (SOC)  with  “mother-daughter”
cholangioscope (SpyglassTM system, Boston Scientific, Natick, MA, United States) is
the most widely used technique and is gradually replacing the first-introduced dual-
operator CS. More recently, ultrathin endoscopes have been introduced, permitting a
direct peroral CS[7].  The main CS clinical indications include both diagnostic and
therapeutic procedures.
The  most  intriguing  of  the  emerging  applications  is  the  characterization  of
indeterminate biliary strictures. In fact, although ERCP has a high specificity (> 90%)
in detecting malignancy, it is burdened by a low sensitivity (about 40%), even when
brushing or biopsy is performed[8,9]; in this setting, CS allows a higher - but still not
satisfying - diagnostic yield by both the direct endoscopic visualization and bioptic
sampling, which is possible during the same procedure. In a recent systematic review
including 456 patients among 10 studies, the pooled sensitivity and specificity of SOC-
guided  biopsies  in  the  diagnosis  of  malignant  strictures  were  60.1%  and  98%,
respectively[10].  Interestingly, the endoscopic visual appearance seems to be more
sensitive  for  malignancy  than  the  targeted  biopsies  (but  at  the  price  of  a  lower
specificity),  as  determined  in  the  2011  study  by  Chen  et  al[11]  and  subsequently
confirmed by the cited review.
The visual impression at CS has emerged as a relevant aid, especially in cases of
non-diagnostic brushing or biopsy performed with ERCP (pooled sensitivity and
specificity 74.7% and 93.3%, respectively), suggesting a possible role in the diagnostic
algorithm. However, there are some major issues to consider. At present, there are no
validated imaging criteria  for  CS,  as  reflected by the sub-optimal  inter-observer
agreement[12]; furthermore, some concerns have been raised about the reliability of a
diagnosis of malignancy based purely on visual appearance.
The main clinical application currently is the management of difficult biliary stones.
CS can be successfully performed after failure of bile duct clearance during ERCP,
guiding electrohydraulic or laser lithotripsy; this approach has been shown to be
effective and safe, with a success rate ranging from 77% to 96% for dual-operator
CS13-16] and 90% to 100% for SOC[11,17,18]. This evidence has made CS-guided lithotripsy
a suitable alternative to EPLBD, as recently evaluated in a randomized controlled trial
(RCT) which showed no differences between the two techniques[19]. However, since
CS is significantly more expensive than EPLBD, a more reasonable approach could be
to limit it to cases of EPLBD failures. Based on the current evidence, we propose an
algorithm of endoscopic treatment for common bile duct stones (Figure 1).
Safety in ERCP: prevention of complications and infections
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Figure 1
Figure 1  Algorithm of endoscopic treatment for CBD stones. CBD: Common bile duct; CS: Cholangioscopy; CS-L: CS-guided lithotripsy; EPBD: Endoscopic
papillary balloon dilatation; EPLBD: Endoscopic papillary large balloon dilation; EST: Endoscopic sphincterotomy; ESWL: Extracorporeal shock wave lithotripsy; ML:
Mechanical lithotripsy.
ERCP is associated with several possible complications, including post-procedural
bleeding, perforations, pancreatitis and cholangitis; their incidence largely depends
on  the  complexity  of  the  procedure,  which  can  be  assessed  by  various  scoring
classifications  (i.e.  the  American Society  for  Gastrointestinal  Endoscopy (ASGE)
grading system)[20,21].
Post-ERCP pancreatitis (PEP) is the most common adverse event in ERCP, with
incidence ranging from 3% up to 10%[22]. Since PEP is associated with a significant
mortality rate (0.7%) as well as an extended hospitalization rate, strategies to prevent
its  occurrence  have  been  largely  investigated.  Among the  many possible  drugs
studied for prophylaxis of PEP, the rectal administration of 100 mg of diclofenac or
indomethacin-proposed for the first  time by Elmunzer et  al[23]  in 2012 -  has been
endorsed by European guidelines based on the evidence obtained from four RCTs
and three meta-analysis[24].
After this first report, additional evidence about the protective role of nonsteroidal
anti-inflammatory drugs (commonly known as NSAIDs) in PEP has been produced
but with conflicting results[25-27]. However, two recent meta-analyses confirmed the
protective role of NSAIDs for PEP, both carried out in high-risk and average-risk
patients[28,29].  In  light  of  these  data,  both  the  latest  European  and  American
guidelines[22,24]  recommend the universal administration of rectal indomethacin in
patients  undergoing ERCP.  To note,  there  are  still  variables  which need further
evaluation, like the best administration route (oral vs rectal), timing (before or after
the procedure) and patients’ selection (high-risk vs everyone)[30].
Another prophylactic measure against PEP is an aggressive intravenous hydration.
In a 2014 study,  Buxbaum et  al[31]  found a significant reduction in PEP incidence
among patients receiving hydration with lactated Ringer’s solution (3 mL/kg per hr
during procedure, 20 mL/kg bolus immediately after, and then 3 mL/kg per hr for 8
hr) versus standard hydration (0% vs 17%, P = 0.016). After this pilot study, more data
about the role of lactated Ringer’s in this setting have been accumulating. Two recent
meta-analyses showed the effectiveness and safety of this strategy[32,33], confirming the
promising role of an aggressive hydration protocol for the prevention of PEP.
Apart from pharmacologic prophylaxis, there are other factors which can impact
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PEP occurrence. A careful patient selection is fundamental to reducing PEP, whereby
ERCP  is  strictly  reserved  for  patients  with  high  probability  of  therapeutic
intervention[22]. In addition, the cannulation technique seems to play an important
role. Wire-guided cannulation, in particular, has been found to significantly reduce
PEP compared to the contrast-assisted technique (RR = 0.51; 95%CI: 0.32-0.82)[34]. The
use of pancreatic duct stent was evaluated in numerous RCTs and a meta-analysis,
which have demonstrated a significant reduction in PEP[35].  Thus, pancreatic duct
stent  placement  is  recommended  in  high-risk  patients  (repeated  inadvertent
pancreatic duct cannulation) by international guidelines[22,24].
In 2013, the Centers for Disease Control and Prevention sent an alert to the FDA
about  a  potential  association  between  multidrug  resistant  bacteria  and
duodenoscopes. Accurate examinations proved that these cases of infection were
occurring despite confirmation that the users were following proper manufacturer
cleansing and disinfection or  sterilization instructions.  For  this  reason,  the FDA
implemented a continuous monitoring program on the three manufacturers (Fujifilm
Medical  Systems  USA,  Inc,  Olympus  Medical  Systems  Corporation,  Pentax  of
America) to warrant appropriate corrective actions.
Duodenoscopes  are  complex  instruments  to  clean  because  of  the  many small
working parts, like the elevator channel. If not adequately cleansed and disinfected,
tissue or fluid from patients can lead to patient-to-patient transmission of infection.
Recently, the Quality Assurance in Endoscopy Committee of the ASGE published a
guideline  for  infection  control  during  gastrointestinal  endoscopy  with  new
indications for reprocessing duodenoscopes, including use of double reprocessing
cycles and uniform or intermittent surveillance programs with the use of a “culture
and hold” policy[36,37]. In a recent systematic review, Olafsdottir et al[38] evaluated the
correlation between concomitantly sampled adenosine triphosphate and bacterial
contamination obtained from the instrument channel and/or elevator mechanism of
the duodenoscope, as an alternative method to bacterial culture for evaluating the
quality of reprocessing. The authors concluded that current data do not support the
direct substitution of adenosine triphosphate for bacterial culture surveillance of
duodenoscopes.
Furthermore, corrective actions from manufacturers have been implemented, such
as the introduction on the market of new duodenoscopes with a single-use disposable
elevator. In the era of single-use devices, like biopsy forceps, snares, sphincterotomes
and  now  disposable  elevators,  we  contemplate  the  use  of  "single-patient  full
equipment  kits,"  so  that  in  the  near  future  we  could  hope  for  a  single-use
duodenoscope too!
Management of malignant and benign biliary strictures
ERCP has a crucial role in the diagnosis and management of cholangiocarcinoma.
Tissue sampling from brushing and biopsy has a low sensitivity, ranging from 18% to
60%[39,40].  Hopefully,  CS  could  play  a  role  in  the  early  diagnosis  of  strictures  of
uncertain nature, without any evidence of metastasis. If the stricture involves the
carrefour or above (Bismuth II-IV), it can be potentially harmful to inject contrast[41] to
enhance  the  intrahepatic  tree  or  try  a  bilateral  drainage  though multiple  stents
placement because of the increased risk of cholangitis[42,43].
Three RCTs have evaluated the outcomes of unilateral and bilateral drainage[43-45].
On one hand, unilateral stenting has higher rates of technical success because it is
easier  than  bilateral  stenting  and  has  a  significantly  lower  rate  of  early
complications[43]. On the other hand, recent data suggest that bilateral drainage has a
higher clinical success rate, lower re-intervention rate and equivalent technical success
rate  compared with unilateral  drainage[45],  due as  well  to  development  in  SEMS
devices and technical improvement. Advanced hilar strictures are challenging to treat
for the most of us, and the common feeling is that bilateral drainage fits better with
physiological function of the biliary tree. From this prospective, we could might want
to reconsider the term of "bilateral and unilateral" as "complete or incomplete" biliary
drainage instead (Figure 2). Plastic stents are recommended when a patient’s expected
survival is < 3 mo, however uncovered SEMSs are cost-effective according to one
RCT[44].
Long patency and removability make fully covered (fc)SEMS appealing for therapy
of benign biliary stricture (BBS) too,  but  the high rate of  migration dramatically
reduces  the  odds  of  stricture  resolution[46].  For  this  reason,  the  Industry  have
developed  a  new  "anti-migration"  designed  SEMS.  In  a  recent  meta-analysis
evaluating  the  clinical  outcome  of  endoscopic  covered  metal  stenting  for  the
resolution of benign biliary stricture, Zheng et al[47] found that the stricture recurrence
in a 4-year follow-up was 11% (95%CI: 8%-14%) with the median stents dwelling time
of 4.4 mo.
The “multi-stenting” treatment (multiple plastic stenting, insertion of the maximum
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Figure 2
Figure 2  Patient with Klatskin’s tumor before (A) and after (B) bilateral or “complete” biliary drainage with uncovered self-expandable metal stent.
number of stents, possible every 3-4 mo, for a total duration of 12 mo; Figure 3) still
represents  the  therapy  of  choice  for  BBS[48],  especially  when  related  to  liver
transplantation and post-cholecystectomy injury, while the recommendation to use
fcSEMS is still weak. In 2016, Coté et al[49] published the results of an RCT regarding
the non-inferiority of fcSEMS to plastic stents with respect to stricture resolution.
Exclusion criteria were bile duct diameter less than 6 mm and intact gallbladder in
whom the cystic duct could be overlapped by a fcSEMS.
Compared with multiple plastic stents (41/48, 85.4%), the resolution rate was 92.6%
(50/54) for fcSEMS and the number of ERCPs was significantly lower in the group of
fcSEMS versus multiple plastic stents (mean, 2.14 vs 3.24; mean difference, 1.10; 95%CI:
0.74-1.46; P < 0.001), thus indicating that fcSEMS was not inferior to multiple plastic
stents after 12 mo in achieving stricture resolution. These data have been recently
confirmed in an RCT for anastomotic biliary strictures after liver transplantation[50].
Tringali et al[51] recently evaluated fcSEMS removability, stricture resolution rate,
and adverse events in 15 patients with chronic pancreatitis and symptomatic main
pancreatic  duct  stricture  located  in  the  head.  Stent  removability  from the  main
pancreatic  duct  was  feasible  in  all  the  cases,  and  90%  of  the  patients  were
asymptomatic after 3 yr. The main adverse event was the “de novo” stricture that
fcSEMS induced in 4 patients (27%), while complete distal migration occurred in 46%
of cases. The high clinical efficacy and removability are encouraging results but, on
the  other  side,  the  high  migration  rate  and  the  occurrence  of  fcSEMS–induced
strictures suggest further evaluation with RCT to assess the role in this setting.
WHAT COULD POTENTIALLY CHANGE IN THE NEAR
FUTURE
Tissue ablation techniques
SEMS occlusion by tissue in-growth frequently occurs with uncovered SEMS inserted
to  treat  hilar  cholangiocarcinoma;  this  may,  therefore,  require  more  frequent
procedures. The endoscopic goal is for adequate biliary drainage to palliate jaundice,
but it also aims to reduce the number of reinterventions. New endoscopic techniques
may extend stent patency and patient survival.
Photodynamic therapy (PDT) offers the possibility of  tumor mass reduction[52]
through the necrosis of the neoplastic tissue due to activation at a specific wavelength
of a photosensitizing agent, given intravenously, which accumulates in malignant
cells. Many studies have compared outcomes with PDT and biliary stenting versus
biliary stenting only in palliation of nonresectable cholangiocarcinoma. Recently
Moloe and colleagues[53] reported positive effects on biliary drainage, survival and
quality of life in patients with advanced cholangiocarcinoma from a systematic review
and meta-analysis comparing PDT with biliary stenting versus stenting alone. The
most common adverse events were cholangitis and phototoxicity. Since cholangitis
occurred in all patients with biliary stenting too, it is inappropriate to relate this effect
to PDT. These data endorse the promising role of PDT even though limitations exist
due to several biases, like small sample size and the heterogeneous methods used for
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Figure 3
Figure 3  Management of post-cholecistectomy benign biliary stricture. A: Before the treatment; B: Multi-stenting treatment; C: Radiological appearance at the
end of treatment.
PDT (percutaneous/endoscopic) and biliary stenting (plastic/SEMS). Well-designed
prospective randomized studies are still needed.
The use  of  SOC for  PDT makes  the  procedure technically  more feasible,  with
shorter fluoroscopy time and longer median survival compared with PDT alone, as
reported by Talreja et al[54].
Radiofrequency ablation (RFA) has been used historically longer as a heat delivery
system for the destruction of primary and secondary hepatic tumors via  localized
coagulative  necrosis.  Recently,  a  new  probe  fit  for  endoscopic  use  has  become
available. A retrospective analysis of patients who have undergone RFA for malignant
biliary obstruction has suggested that RFA may prolong survival in patients with
advanced cholangiocarcinoma, but these findings need to be confirmed by controlled
studies. Moreover, adverse events like pain, cholecystitis, hemobilia and injury to
adjacent vascular structures may occur, and this suggests that caution must be taken
for the endoscopic-guided use of this technique.
Training in biliopancreatic endoscopy
Competency  in  advanced  procedures  such  as  ERCP  and  EUS  have  been  long
analyzed. For ERCP, selective cannulation in at least 90% of procedures, accurately
interpreting endoscopic and radiologic images, and successful sphincterotomy and
stent placement are mandatory for the achievement of competency[55,56]. We know that
this goal is hard to accomplish for young endoscopists and it takes a long period
(according to the latest evidence,  3-yr fellowship or 1 yr of advanced endoscopy
training are required[57,58])  and a large amount of  procedures (> 200 ERCP under
supervision of a tutor, along with 80 sphinterotomies and 60 stent insertions[59]). The
EUS learning curve is not easier than that of the ERCP one and includes at least 225
hands-on cases under supervision[60].
In  the  past  few  years,  simulators  have  been  introduced  with  the  aim  of
approximating the human anatomy and recreating the difficulties encountered during
real-life situations in human patients. Competency-based fellowship programs have
spread,  to  validate  trainee  assessment  as  well.  In  2018,  Wani  and  colleagues[61]
evaluated, in a prospective multicenter cohort study, quality indicator adherence
during the  first  year  of  independent  practice  among physicians  who completed
endoscopic training with a systematic assessment of competence. They used TEESAT
(a procedure-specific  competence assessment  tool  with strong validity  evidence
endorsed  by  the  ASGE)  to  assess  EUS and ERCP skills  in  a  continuous  fashion
throughout training. At the end of training, overall technical (EUS, 91.7% and ERCP,
73.9%) and clinical (EUS, 91.7% and ERCP, 94.1%) competence were achieved by most
of the trainees, thus confirming the effectiveness of training programs.
EUS  and  ERCP  have  both  evolved  from  being  a  diagnostic  procedure  to  a
therapeutic procedure. Always more often in our endoscopy rooms, switches from
EUS to ERCP or vice versa happen. Single-session EUS and ERCP have been shown to
be accurate and effective, with minimal complication rates[62].
There are no clear data as to whether a single operator performing both procedures
has better outcomes compared to those achieved by two different operators. EUS-
guided biliary drainage has emerged as an alternative procedure after failed ERCP
and ERCP, but expertise is needed to perform some steps, such as stent insertion. Yet,
how many endoscopists can shift from ERCP to EUS is unknown. Maybe this is the
time not to consider separate programs of education for learning ERCP and EUS but
to instead consider one just  for those who are really interested in interventional
endoscopy. Endoscopists with experience in both techniques will  be increasingly
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important, suggesting a parallel formation in training plans for all future endoscopists
with an interest in the area.
Biodegradable and drug-coated stents
Therapy with plastic or metallic stent for benign disease requires repeated endoscopy
for stent removal. To avoid this, self-expanding biodegradable biliary stents (BDBSs)
have recently become available for ERCP. In the past, hyperplasia or restricturing
secondary to biodegradable stents encountered in the gastrointestinal stenting for
benign diseases limited further use. Several studies on animal and human models to
investigate the use of BDBSs with polylactide or polydioxanone in bile ducts showed
good biocompatibility of BDBS, with a negligible histologic foreign body reaction and
low risk of restricturing[63,64]. Siiki et al[63] evaluated the effectiveness and safety of a
novel BDBS in 13 patients with iatrogenic cystic duct leaks (n = 7) and BBS (n = 6).
Complete bile leak resolution was achieved in all patients and the clinical success rate
in BBS was 83% in the median follow-up period of 21 mo (range: 14-25 mo). Repeated
MRI during the first year demonstrated the gradual degradation pattern.
These data seem promising,  but the small  number of cases and the absence of
control groups suggest careful evaluation and further controlled studies on long-term
clinical results.
Metal stenting for malignant biliary strictures may fail because of tumor ingrowth
or overgrowth of excessive epithelial or malignant cells. Drug-coated stents have been
used for  a  long time in  coronary artery  disease  to  reduce  the  incidence  of  stent
malfunction.  Only  paclitaxel  has  been  trialed  in  humans  with  malignant
obstruction[65,66] and provided encouraging results. Suk and colleagues[65] found overall
patency rates at 3, 6 and 12 mo of 100%, 71% and 36%, respectively, in 21 patients with
unresectable malignant biliary strictures treated with metallic stent coated with a
paclitaxel-incorporated membrane.
The biggest limit to research in this field is that there are no cheap reproducible
models to develop an ideal drug-eluting stent able to inhibit malignant cells growing
with reasonable histologic tolerance to the biliary epithelium too.
Sedation in ERCP
ERCP may result in a prolonged procedure requiring adequate sedation.
According to the ASGE statement about non-anesthesiologist administration of
propofol  for  gastrointestinal  endoscopy[67],  the  administration  of  propofol  and
standard sedation by non-anesthesiologists is equivalent in terms of efficacy and
safety when done in a setting of properly trained staff and accurate patient selection.
Moreover, the use of anesthesiologist-administered propofol for selected patients with
no risk factors for sedation-related complications is very costly and does not improve
safety or procedural outcomes. The long-standing argument among anesthesiologists
about the use of propofol by non-anesthesiologists is supported by the absence of an
antidote  and by  the  rapid  transition  from a  level  of  moderate  sedation  to  deep
sedation or even general anesthesia, making it therefore unmanageable for a non-
anesthesiologist.  Moreover,  the  label  indications  report  that  it  ‘‘should  be
administered only by persons trained in the administration of general anesthesia’’ and
in 2012, the European Society of Anaesthesiology retracted its endorsement to the
guideline on non-anesthesiologist  administration of propofol for gastrointestinal
endoscopy,  published  together  with  the  European  Society  of  Gastrointestinal
Endoscopy and the European Society of Gastroenterology and Endoscopy Nurses and
Associates[68]. These issues have deep medico-legal implications, above all in some
countries in Europe, that do not make us all have sweet dreams.
CONCLUSION
In the past 30 yr, the role of ERCP has changed deeply.
Radical developments have increased our performance in the diagnostic field, such
as with CS, and in the therapeutic field, such as with the advent of SEMS or with the
management of "difficult biliary stone” removal. Safety has improved too with the
prevention of ERCP-related complications and infections (Table 1).
On the other hand,  there are still  wide grey areas.  We are still  far  from using
biodegradable stents and this means repeating ERCP in patients with benign biliary
strictures. Unlike percutaneous therapy of acute myocardial infarction, we have not
yet  applied  drug-coated  stent  implantation.  Even  if  non-anesthesiologist
administration of propofol has been found to be safe in an evidence-based assessment,
there is  no endorsement from the Anesthesiologists  and this  can represent a big
limitation in some countries.
RFA and PDT are promising tissue ablation techniques; the effect seems to not only
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Table 1  Summary of current evidence for each topic
Topic Current evidence
Management of " difficult" choledocolithiasis EST plus EPLBD
Cholangioscopy Electrohydraulic or laser lithotripsy/tissue sampling
Safety in ERCP: complications and infections
PEP Rectal administration of 100 mg of diclofenac or indomethacin and
pancreatic duct stenting in high-risk and average-risk patients/aggressive
intravenous hydration/wire-guided cannulation
Multi-drug resistant bacteria and duodenoscopes Single-use disposable elevator
Management of malignant and benign biliary strictures Bilateral drainage for hilar strictures with uSEMS /“multi-stenting”
treatment for benign biliary strictures
Tissue ablation techniques PDT with biliary stenting in advanced cholangiocarcinoma (more studies are
needed)
RFA for advanced cholangiocarcinoma (more studies are needed)
Training in biliopancreatic endoscopy ERCP: at least 200 procedures under supervision of a tutor with 80
sphincterotomies and 60 stent insertions
EUS: at least 225 hands-on cases under supervision
Biodegradable and drug-coated stents BDBSs with polylactide or polydioxanone showed good biocompatibility
(more studies are needed)
Only paclitaxel has been trialed in humans with malignant obstruction
(more studies are needed)
Sedation in ERCP Propofol and standard sedation by non-anesthesiologists is equivalent in
terms of efficacy and safety in a setting of properly trained staff and accurate
patient selection (ASGE): ESA retracted its endorsement to ESGE and
ESGENA
ASGE: American Society for Gastrointestinal Endoscopy; BDBSs: Self-expanding biodegradable biliary stents; EPLBD: Endoscopic papillary large balloon
dilation;  ESA:  European  Society  of  Anaesthesiology;  ESGE:  European  Society  of  Gastrointestinal  Endoscopy;  ESGENA:  European  Society  of
Gastroenterology and Endoscopy Nurses and Associates; EST: Endoscopic sphincterotomy; PDT: Photodynamic therapy; PEP: Post-ERCP pancreatitis;
uSEMS: Uncovered self-expandable metal stent; RFA: Radiofrequency ablation.
be localized but it may prolong the survival of patients with advanced cholangiocar-
cinoma; however, a large sample size from a controlled study is still needed.
ERCP has given us the chance to directly access the biliary tree and pancreatic duct
and this has been a precious achievement, but we have focused our attention to find
the best way to treat biliopancreatic disease under the "one size fits all" motto. In the
near future, direct visualization and tissue sampling might lead us to understand
better the genomic alterations in every single patient, thus allowing for "personalized"
targeted molecular therapy.
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